Last Updated: 04/06/07
About the Director
James H. Doroshow, M.D., FACP, has been the Director of the Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), since 2004. He fosters collaboration with other NCI divisions and offices, as well as extramural scientists and clinicians, patient advocates, and professional cancer organizations. He leads the DCTD professional staff, who represent a wide array of scientific specialties...
Overview
The Division of Cancer Treatment and Diagnosis (DCTD) collaborates with other NCI components as the world's largest sponsor of clinical cancer research.
The multidisciplinary staff members of DCTD identify the most promising areas of science and technology for development of better diagnostic and therapeutic interventions for patients with cancer. A roster listing full-time DCTD staff as well as contractors is appended to this report.
The division takes prospective detection and treatment leads, facilitates their paths to clinical application, and expedites the initial and subsequent large-scale testing of new agents and interventions in patients. By determining the highest priority questions that can be examined in the laboratory and through clinical trials, DCTD ensures that appropriate mechanisms and resources are available for the development of novel interventions for the wide range of cancers affecting children and adults.
Another major objective for the division is increasing the scientific depth at which new treatments are being evaluated while coordinating the administration and conduct of clinical trials with all other NCI components involved in the pursuit of clinical studies.
DCTD scientists support programs to pursue high-risk research that may yield great benefits for patients with cancer but may be too difficult or risky for industry or academia to undertake. This includes a particular emphasis on the development of unique molecular signatures for cancer and molecular assays and imaging techniques that will guide oncologic therapy in the future.
